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Context: Mutations to isocitrate dehydrogenase (IDH) appear to play a prognostic or predictive role 
in several neoplasias. Immunohistochemical staining designed to detect a specific R132H mutation to 
IDH1 showed expression in the normal adrenal cortex, raising interest to study the potential role of 
IDH1 in the pathogenesis of adrenocortical tumors.
Objective: The objective of this work is to study the role of IDH1 and its mutations in adrenocortical 
tumors.
Design and patients: IDH1 R132H immunohistological staining was performed on a cohort of 197 
adrenocortical tumors. The exon of the IDH1 gene was sequenced in 16 tumors.
Results:  Positive IDH1 R132H immunohistochemical staining correlated with a better prognosis 
among patients with a malignant adrenocortical tumor. However, IDH1 R132H immunohistochemistry 
did not distinguish between local and metastasized tumors. We were unable to identify IDH1 
mutations among our adrenocortical tumors using a targeted next-generation sequencing panel or via 
exon sequencing.
Conclusions: Among adrenocortical carcinomas, IDH1 R132H immunopositivity correlated with a 
better prognosis. Thus, IDH1 R132H immunohistochemical staining could serve as a prognostic or 
as a potential predictive marker in adrenocortical carcinomas. Further research is needed to iden-
tify the possible alterations in IDH1 that could explain our findings, because we identified no known 
mutations to the IDH1 gene.
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Adrenocortical tumors have emerged as an important clinical issue given the wide-
spread use of high-resolution imaging and the increased prevalence of these lesions. Most 
adrenocortical tumors are benign adenomas that can be cured through the unilateral re-
moval of the adrenal gland. Rare adrenocortical carcinomas are accompanied by a poor 
prognosis, and postoperative treatment options for them remain scarce. Understanding the 
pathogenesis of adrenocortical tumors would lead to the more accurate diagnosis of these 
tumors and may offer targets for the treatment of malignant tumors.
Isocitrate dehydrogenase (IDH) is a metabolic enzyme, ubiquitous in all cells of the body, 
responsible for the oxidation of isocitrate to α-ketoglutarate and the conversion of NAD(P)+ 
to NAD(P)H. IDH exists in 3 isoforms. Mutations of IDH isoforms 1 and 2 were first identified 
in gliomas [1], and have since been reported in several neoplasias [2-5]. The mutated form 
of IDH gains neomorphic activity, resulting in the conversion of α-ketoglutarate to an 
oncometabolite, D-2-hydroxyglutarate. The subsequent accumulation of the oncometabolite 
results in epigenetic dysregulation by inhibition of the α-ketoglutarate–dependent histone 
and DNA demethylases, and a block in cellular differentiation [6, 7].
In gliomas, the status of an IDH mutation is an important diagnostic and prognostic 
feature, determined during routine clinical practice. IDH mutations occur in most lower-
grade gliomas and secondary glioblastomas, indicative of a distinctive pathogenesis and a 
better prognosis compared to primary glioblastomas. A specific R132H mutation to IDH1 
accompanies approximately 80% of all IDH mutations in gliomas [8], and can be depicted 
from formalin-fixed, paraffin-embedded (FFPE) tissues through immunohistochemistry 
using an antibody against the mutated protein [9]. In adrenocortical tumors, IDH1 and 
IDH2 mutations have thus far remained unreported. Interestingly, another research group 
in Helsinki found an immunohistochemical positivity for IDH1 R132H in the normal ad-
renal cortex (oral communication). This finding piqued our interest in examining the IDH1 
R132H expression in adrenocortical tumors.
Thus, we aimed to study the role of IDH1 and its possible mutations in a large cohort of 
clinically verified adrenocortical tumors.
1. Methods
A.  Clinical Data and Tumor Material
We identified all adult patients who underwent surgery for a primary adrenocortical tumor 
at the Department of Surgery, Helsinki University Hospital between 1990 and 2003. The se-
ries comprised 195 patients with 197 tumors (2 patients had 2 separate tumors). The tumor 
specimens were taken from the archives of the Department of Pathology, and clinical data 
were collected from patient records. We gathered survival data and cause of death infor-
mation from the Population Register Center and Statistics Finland. The Ethics Committee 
of Helsinki University Hospital and the National Supervisory Authority for Welfare and 
Health approved the study protocol.
The clinical characteristics of tumor patients are shown in Table  1. Among the 195 
tumor patients, 14 died from adrenocortical carcinoma. These patients had metastatic di-
sease and their survival time ranged from 0.30 to 6.84 years (median, 2.05 years; mean, 
2.97 years) after primary surgery. During follow-up, 36 patients died of causes other than 
an adrenocortical tumor. Among patients alive at the end of the study, the follow-up time 
ranged from 7.84 to 21.83 years (median, 11.27 years; mean, 12.64 years).
B.  Material for Genetic Analysis
To identify mutations of IDH1 at Arg132 using amplicon-based hot spot panel sequencing, 
we chose 10 tumors with Weiss scores of 3 to 9, 5 of which exhibited strong positive and 5 






/jes/article-abstract/4/4/bvaa018/5739627 by guest on 28 M
ay 2020
doi: 10.1210/jendso/bvaa018 | Journal of the Endocrine Society | 3
For IDH1 gene sequencing from the FFPE tumor material, we chose an additional 10 
tumors, 5 tumors with Weiss scores of 0 to 2 with positive IDH1 R132H immunohistochemistry, 
and 5 tumors with Weiss scores of 3 to 9 with low positivity. In total, we analyzed 20 tumors.
Among these 20 tumors, we had fresh-frozen tumor material available for IDH1 gene 
sequencing for 16 tumors.
C.  Histopathology
The histopathological diagnosis using the Weiss score [10, 11] for each tumor was reviewed 
by 2 endocrine pathologists (M.P. and J.A.) based on hematoxylin-and-eosin–(H&E) stained 
sections. The novel Helsinki score, introduced by the authors [12], was also determined. The 
Helsinki score consists of 3 × mitotic rate (> 5/50 hpf) + 5 × presence of necrosis + prolifer-
ation index (Ki67/mib index). A score greater than 8.5 indicates metastatic carcinoma with 
a sensitivity of 100%.
D.  Tissue Microarray Construction
Tissue microarray (TMA) blocks were constructed from archived surgical formalin-fixed, 
paraffin-embedded specimens. Representative areas of each tumor were chosen from 
Table 1. Clinical and histological characteristics of tumors, and distribution of isocitrate dehydro-







No. of tumors   197 183 14  
Age, y Range  24-82 24-82 32-76 .777
Mean  54.2 54.3 53.5  
Median  55 54 55.5  
Sexa Male  66 60 6 .560
Female  129 121 8  
Side Right  101 93 8 .784
Left  96 90 6  
Size, cm Range  0.5-28.0 0.5-28.0 4-22 < .001
Mean  3.4 2.8 12.1  
Median  2 2 12.5  
Hormonal secretion       
 Aldosterone No.  96 94 2 .010
%  49 51 14  
 Cortisol No.  74 67 7 .394
%  38 37 50  
 Androgens No.  11 7 4 .004
%  6 4 29  
 Inactive No.  29 24 5 .038
%  15 13 36  
Weiss score 0-2  164 164 0 < .001
 3-9  33 19 14
Helsinki < 8.5  177 177 0 < .001
scoreb ≥ 8.5  17 3 14
IDH1 R132H scorec 0  133 122 11 .359
1-3  62 59 3
  1 46 44 2  
  2 14 13 1  
  3 2 2 0  
Abbreviation: IDH1, isocitrate dehydrogenase 1.
aOne man and one woman had 2 separate tumors.
bThe Helsinki score was determined for 194 tumors.
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H&E-stained slides. Using a semiautomatic TMA instrument (Beecher Instruments), three 
1-mm cores were obtained from each histologically benign (Weiss score 0-2) tumor, and 6 
cores were taken from the histologically malignant (Weiss score 3-9) tumors. In addition, 2 
cores from the normal adrenal cortex were taken from each specimen.
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E.  Immunohistochemistry
TMA blocks were cut into 4-µm sections. For antigen retrieval, slides were treated in a 
PreTreatment module (Lab Vision Corp) in a Tris-EDTA (pH 9.0) buffer for 20 minutes 
at 98°C. Immunohistochemical staining was performed using the EnVision polymer de-
tection kit (Dako) in a LabVision Autostainer (Thermo Fisher Scientific). Sections were 
incubated with the mouse monoclonal IDH1 R132H antibody (clone H09, Dianova) [13] 
at a dilution of 1:20 for 30 minutes at room temperature. The slides were counterstained 
with Mayer’s Hematoxylin (Lillie’s Modification; Dako) and mounted using Mountex 
(Histolab).
F.  Interpretation of Immunohistochemical Staining
IDH1 R132H immunohistochemical expression was determined in 195 tumors. Staining 
was scored independently by 2 experienced pathologists (M.P. and O.T.). Any discrepancies 
between scores were resolved through consensus.
The intensity of the cytoplasmic staining of IDH1 R132H, that is the amount of positively 
staining granules, was scored on a scale from 0 to 3. The staining was fairly evenly distrib-
uted throughout the tumor tissue. Therefore, the extension of the staining was not scored. 
Negative cytoplasmic staining was scored as 0, weakly positive as 1, moderately strongly 
positive or a focally strong positivity as 2, and a strong positivity as 3. For all of the stained 
samples for each tumor, the highest score was used for further analysis.
G.  Amplicon-Based Hot-Spot Panel Sequencing
DNA was extracted from 10 FFPE samples following deparaffinization using the Maxwell 
LEV Blood DNA Kit (Promega Corp) according to the manufacturer’s instructions. The 
tumor content of each sample was evaluated from H&E-stained slides by an experienced 
pathologist (M.P.).
DNA was subjected to library preparation using the Ion AmpliSeq Cancer Hotspot Panel 
version 2, designed to target 2800 COSMIC mutations from 50 oncogenes and tumor sup-
pressor genes, and sequenced on the Ion Torrent PGM System (Thermo Fisher Scientific). 
The panel covers 15 and 11 hot-spot regions in IDH1 including the R132 and IDH2 genes, re-
spectively. Library preparation, template preparation, and sequencing were carried out ac-
cording to the manufacturer’s instructions (Life Technologies). Data analysis was performed 
using the Torrent Suite Software version 4.0. After trimming and alignment to the hg19 
human reference genome, sequence variants were detected using the VariantCaller version 
4.0. The Ion Reporter software version 4.0 was used to filter out noncoding and polymorphic 
variants.
H.  Hybridization Capture–Based Targeted Sequencing
For preparing paired-end libraries, 7000 to 32 000 ng of DNA extracted from FFPE blocks 
(n = 20) were used. For fresh-frozen samples (n = 16), 2300 to 14 300 ng of DNA was used as 
the input (ThruPlex DNA-Seq Kit, Rubicon Genomics). Target enrichment was performed 
using the SeqCap EZ Comprehensive Cancer panel (Roche NimbleGen). The panel covers 
9 exons and the 5’ untranslated region of the IDH1 gene, including the mutation sites of 
the Hot Spot Panel version 2. The enriched libraries were sequenced using the HiSeq2000 
instrument with a paired-end 100-bp read length. Sequence analysis and variant calling 
were performed by an in-house bioinformatics pipeline (VCP, variant calling pipeline [14]). 
In addition to variant calling algorithms, IDH1 mutation hot-spot loci were also visually 
inspected from the.bam files using IGV (Integrative Genome Viewer [15]). The library prep-
aration, sequencing, variant calling, and data analysis for this experiment were performed 
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I.  Statistical Analysis
Results are stated as the median, range, or the number of patients. Comparison between 
groups was performed using the Mann-Whitney test and the Fisher exact test for contin-
uous and dichotomous variables, respectively. Correlations were tested by calculating the 
Spearman rho correlation coefficient. The Kaplan-Meier method with the log-rank test was 
used to compare survival between groups. We considered a P value less than .05 as sta-
tistically significant and relied on 2-tailed tests. All analyses were performed using SPSS 
version 24 (IBM).
2.  Results
A.  Isocitrate Dehydrogenase 1 R132H Immunohistochemical Staining of Normal Adrenal 
Cortex and Adrenocortical Neoplasias
The IDH1 R132H immunohistochemical staining appeared as granular cytoplasmic posi-
tivity in adrenocortical tumors. A similar staining was seen in the normal adrenal cortex 
(Fig. 2). The intensity of the staining, that is the amount of positive granules, varied. Fig. 2 
shows the pattern and differences in the IDH1 R132H stainings.
The IDH1 R132H staining appeared both in benign and malignant tumors, and negative 
vs positive staining could not distinguish between local and metastatic disease (P = .359). In 
the entire tumor material, the IDH1 R132H staining (negative vs positive) and Weiss score 
(0-2 vs 3-9) did not correlate (P = .312) nor did the IDH1 R132H staining and Helsinki score 
(< 8.5 vs ≥ 8.5; P = .212). In histologically malignant tumors (Weiss score 3-9), the IDH1 
R132H staining (negative vs positive) correlated with the Helsinki score (< 8.5 vs ≥ 8.5; 
R2 = –0.437, P = .012).
Aldosterone secretion of the tumor correlated with a weak IDH1 R132H staining 
(R2 = –0.163, P = .023), whereas cortisol secretion correlated with a strong IDH1 R132H 
staining (R2 = 0.243, P = .001). We found no correlation between the IDH1 R132H staining 
and testosterone secretion (R2 = 0.071, P = .326) or with hormonal inactivity (R2 = –0.132, 
P = .066).
B.  Prognostic Significance of Isocitrate Dehydrogenase 1 R132H Immunohistochemistry in 
Adrenocortical Carcinomas
To examine the possible prognostic significance of the IDH1 R132H staining in 
adrenocortical carcinomas, we chose all 33 tumors with a Weiss score of 3 to 9, defined 
as malignant according to the World Health Organization’s classification. Patients with 
a positive IDH1 R132H staining survived longer than patients with a negative staining 
(P = .031; Fig. 3).
C.  Amplicon-Based Hot-Spot Panel Sequencing
The data analysis of the hot-spot mutations revealed no mutations in the IDH1 or IDH2 
genes, with a sensitivity of 2%.
D.  Hybridization Capture–Based Targeted Sequencing
From the FFPE-derived samples, we received no informative sequencing data. Initial 
sequencing provided the mean target coverage of the sequencing depth after the removal 
of duplicates. Sequencing delivered depths of 115 to 505×; yet, after polymerase chain reac-
tion (PCR) duplicate removal, the informative depth diminished to 2 to 13×. Evidently, the 
samples contained sufficient DNA molecules (mass), but the mass was heavily cross-linked 
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seemingly well in PCR amplicons–based methods, but lacks true somatic resolution given 
the limited number of accessible DNA template molecules.
Using the same protocol for the DNA from fresh-frozen samples, we yielded sequencing 
depths ranging from 100 to 500× after PCR duplicate removal, which enabled us to perform 
somatic mutation calling. We failed to identify any known hot-spot mutation or any novel 
variants in the IDH1 gene or the untranslated regions [16].
3.  Discussion
In a large cohort of adrenocortical tumors, we found that mutation-specific IDH1 R132H 
immunopositivity correlated with a better prognosis among adrenocortical carcinoma 
patients, suggesting a distinct pathogenic pathway among these tumors. However, IDH1 
R132H immunohistochemistry did not correlate with the prognostic scoring systems used 
for adrenocortical tumors, such as the Weiss score or the Helsinki score, nor did it distin-
guish between local and metastasized disease. However, through genetic analysis, we failed 
to identify any known or novel IDH1 mutations in our adrenocortical tumor cohort.
The IDH1 R132H antibody used for the immunohistochemical staining was developed 
to specifically recognize the R132H mutated form of the IDH1 protein, the most frequent 
mutation seen in secondary glioblastomas. All reported pathogenic mutations of IDH1 are 
Figure 2. Staining pattern of isocitrate dehydrogenase 1 (IDH1) R132H 
immunohistochemistry (IHC) in normal adrenal cortex and adrenocortical tumors. A, 
Hematoxylin and eosin staining and B, IDH1 R132H IHC of normal adrenal cortex. C) Score 
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heterozygous missense point mutations that alter the conserved binding site of the homodimer 
enzyme. These most often occur at codon 132 by replacing arginine with another amino acid. 
To improve the diagnostic procedure of gliomas, Capper et al [9] developed the IDH1 R132H 
antibody that binds to IDH1, where histidine replaces arginine 132. This mutation-specific 
antibody does not detect other mutated forms of IDH1, such as R132S, R132C, R132G, or 
R132L, nor does it bind to or cross-react with wild-type IDH1. We found only one study that 
reported any positivity in tumor cells using the IDH1 R132H antibody in tumors negative 
for the R132H mutation through DNA sequencing. Amary and colleagues [4] studied IDH1 
and 2 mutations in cartilaginous tumors, finding 5 R132H immunopositive tumors in which 
the mutation remained undetected through sequencing. They assumed that the amount 
and proportion of tumor cell DNA in the sample was too low for sequencing, concluding that 
the IDH1 R132H immunohistochemical staining was, in fact, more sensitive in identifying 
the mutation than sequencing. Against this background, we were surprised to find IDH1 
R132H staining in the normal adrenal cortex and in adrenocortical tumors. Furthermore, 
we observed a granular cytosolic staining similar to that in IDH1 R132H–mutated gliomas, 
although less intensive. To verify the specific R132H mutation of IDH1in these tumors, we 
performed a next-generation sequencing mutational analysis of codon 132, but failed to 
detect any of the previously reported mutations. Therefore, we searched for other possible 
mutations and sequenced the IDH1 exon of 16 tumors. This method revealed no relevant 
IDH1 mutations. Thus, the discrepancy between the positive immunohistochemical expres-
sion in the adrenal cortex and in the adrenocortical tumors and the negative mutation 
remains unclear. We speculate that there may be a posttranscriptional modification of the 
RNA or a conformational alteration of the protein.
Because adrenocortical carcinomas carry a poor prognosis and postoperative treat-
ment options thus far remain limited, new treatment targets are needed. Mutated IDH 
offers a distinct target for specific, individualized therapies. Small-molecule inhibitors 
of mutated IDH and peptide vaccines are being investigated for treating IDH-mutated 
neoplasms [17, 18]. Binding of the IDH1 R132H antibody to a proportion of adrenocortical 
tumors indicates that the new IDH-targeted therapies could benefit this subset of tumor 
patients.
A major advantage to our study is the large cohort size and the comprehensive follow-up 
data available for all patients. The fact that IDH1 R132H immunohistochemical stainings 
revealed a significant difference in survival between immunopositive and immunonegative 
malignant tumors indicates that the antibody detects an epitope with clinical relevance. 
Figure 3. Survival according to isocitrate dehydrogenase 1 (IDH1) R132H immunopositivity 
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The survival difference could be associated with the natural disease progression or the 
treatment response of different tumor subtypes. One weakness of our study stems from our 
inability to identify the epitope that the IDH1 R132H antibody binds to in adrenocortical 
tumors.
In conclusion, among adrenocortical carcinomas, IDH1 R132H immunopositivity 
correlated with a better prognosis. Thus, IDH1 R132H staining could serve as a prognostic 
or as a predictive marker in adrenocortical carcinomas, discerning a subset of tumors 
with a particular pathogenic pathway. Further research is needed to uncover the possible 
alterations in IDH1 that explain our findings, because we failed to find mutations to the 
IDH1 gene.
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